Multiple Sclerosis and Trigeminal Neuralgia: A Well-Noted Association with Unknown Occurrence as a Presenting Symptom: Our Experience in Multi Centric Study

Luigi V Berra1, Daniele Armocida1*, Andrea Di Rita2, Luca D Angelo1, Valerio Di Norcia1 and Antonio Santoro1

1Department of Neurosurgery, Policlinico Umberto I, La Sapienza of Rome University, Italy
2Department of Neurosurgery, La Sapienza of Rome University, Italy

ABSTRACT

Objective: The association between trigeminal neuralgia (TN) and multiple sclerosis (MS) is well established. In many cases series the frequency of TN is reported in patients with MS but information regarding the frequency of trigeminal pain as a symptom of disease onset is lacking. We present a multi centric analysis of SM-patients affected by TN where we investigated the onset of symptomatology and a current literature analysis.

Patients and Methods: We prospectively acquired clinical and radiological information of patients with MS and with TN that were visited at our clinics in two different departments. A pertinent literature review was carried out as well. We investigated the prevalence of TN in patients with MS and we noted whether facial pain was the symptom of MS onset.

Results: A total of 718 patients with multiple sclerosis were analyzed, of which 63 presented TN. The neuropathic facial pain was the presenting symptom of MS in 3 patients, that constituted 0.4% of cases. The results reported in the literature confirm a frequency of 0.4-1% of the cases in which the first symptom of MS is TN and are like those observed in our study.

Conclusions: Is important to investigate the rate of debut of TN in SM patients to set up the correct diagnostic and therapeutic program. Among the different types of neuropathic pain, TN in MS patients are a difficult to treat with a relevant impact on the quality of life. TN constitutes a clinical picture frequently associated with the MS. Nevertheless, TN as a clinical manifestation of the onset of MS is a rare occurrence and is just noted that is rarely the first symptom of disease.

KEYWORDS: Multiple sclerosis; Trigeminal Neuralgia; Facial Pain; Secondary Trigeminal Neuralgia

Quick Response Code: Address for correspondence: Daniele Armocida, Department of Neurosurgery, Policlinico Umberto I, La Sapienza of Rome University, Italy
Received: February 07, 2020 Published: February 25, 2020
How to cite this article: LV Berra, D Armocida, DR Andrea, DA Luca, DN Valerio, SAntonio. Multiple Sclerosis and Trigeminal Neuralgia: A Well-Noted Association with Unknown Occurrence as a Presenting Symptom: Our Experience in Multi Centric Study. 2020 - 1(5) OAJBS.ID.000145.
HIGHLIGHTS
1. Multiple sclerosis is associated with different pain symptoms.
2. Trigeminal neuralgia is frequently associated to multiple sclerosis.
3. Trigeminal neuralgia as the first symptom of multiple sclerosis is a rare event.

INTRODUCTION
Multiple sclerosis (MS) is a chronic neuroinflammatory disease that affects the central nervous system, characterized by a variety of symptoms due to demyelination and axonal degeneration of the white matter of central nervous system. The reported prevalence of MS varies in different studies and countries and is reported between 60 and 200 cases per 100 [1]. Sensory disturbances and pain are common symptoms of MS [2,3]. Pains of any kind are symptoms frequently associated with MS. Among the various painful manifestations of MS, Trigeminal Neuralgia (TN) represents the most disabling and complex management neuropathic pain [4-7]. TN is a well-recognized cause of facial pain in the general population, although it is a relatively rare condition with a lifetime prevalence of up to 0.3% [8]. Secondary TN, both in the classical form and in the form of facial neuropathic pain, is an event that often accompanies this disease [9,10]. In many cases series the frequency of TN is reported in patients with MS but information regarding the frequency of trigeminal pain as a symptom of disease onset is lacking. In this study we aimed to investigate the incidence rate of TN as an onset symptom in a SM population and correlates these data with the current literature.

PATIENTS AND METHODS
We prospectively acquired clinical and radiological information of patients with MS and with TN that were visited at our clinics. We have analyzed the data acquired in a 10-year period, from January 2010 to December 2019, in two hospitals (Ospedale San Carlo Borromeo, Milan - Italy and Policlinico Umberto I - Sapienza, Rome - Italy), the prevalence of TN in patients with MS and we noted whether facial pain was the symptom of MS onset. The information acquired includes the presence of neuropathic facial pain and which was the symptom of onset of demyelinating disease. For all the included patients we recorded age, sex, location of pain, trigeminal root involved, clinical onset, time of diagnoses of SM. The diagnoses of SM was obtained in a specific neurological center following, radiological, clinical obtained by Macdonald criteria [11]. It was agreed on that MS patients who had received a diagnosis of TN at any time, prior verification, during a routine clinical visit, by motor symptoms (14%), dysarthria and tremor (11%) and sphincter dysfunction (6%) (Table 1).

RESULTS
A total of 718 patients with MS where analyzed, of which 63 presented TN (8.8%). Of the 63 patients with neuropathic facial pain, only in three of them this was the initial symptom. The most common presenting symptoms were paraesthesia (26%) vertigo and dizziness (18%) and ocular disturbances (16%), followed by motor symptoms (14%), dysarthria and tremor (11%) and sphincter dysfunction (6%) (Table 1).

Table 1: Presenting symptoms of 718 patients with MS. A table show the characteristic onset of symptoms in our series.

<table>
<thead>
<tr>
<th>First Symptom of MS</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraesthesia</td>
<td>26%</td>
</tr>
<tr>
<td>Vertigo and dizziness</td>
<td>18%</td>
</tr>
<tr>
<td>Ocular disturbances</td>
<td>16%</td>
</tr>
<tr>
<td>Motor symptoms</td>
<td>14%</td>
</tr>
<tr>
<td>Cerebellar (dysarthria and tremor)</td>
<td>11%</td>
</tr>
<tr>
<td>Sphincter dysfunction</td>
<td>8%</td>
</tr>
<tr>
<td>Others</td>
<td>7%</td>
</tr>
</tbody>
</table>

All the patients included underwent a brain MRI scan included an high field 3 Tesla volumetric study with the following sequences: T2w, FLAIR, isotropic volumetric T1-weighted magnetization-prepared rapid acquisition gradient echo (MPRAGE) before and after intravenous administration of paramagnetic contrast agent; diffusion tensor sequences (DTI) completed our protocol for what concerns relationships between vascular and neural structures in the cerebellar - pontine angle's cistern.

The informed consent was approved by the Institutional Review Board of our Institution and Area Vasta Emilia Nord Ethics Committee approval was obtained for this study. Before medical treatment and surgical procedure, all the patients gave informed written explicit consent after appropriate information. Data reported in the study have been completely anonymized. No treatment randomization has been performed. This study is perfectly consistent with Helsinki declaration of Human Medical Research.

Figure 1: The image is an axial T2 weighted image on MRI illustrating typical vascular brainstem involvement, with a right involvement of the transverse pontine fibers near the trigeminal tract. The image on the right is an axial T2 weighted image of the sovratentorial space of an MS-patient, showing typical peripherally disseminated white matter lesions.
Pain other than facial neuropathic pain was reported as a symptom of onset in 3% of cases. Ultimately, in our experience, TN was the presenting symptom of MS only in 3 patients out of 718, which represents 0.4% of cases (Figure 1). The overall average age of onset was 41.3 years +/- 9.3 y, with a female to male ratio of 2.3 to 1. There was no significant difference in the age of onset or average age between two group of MS patients with and without TN.

DISCUSSION

The association between SM and TN is well known [12,13], and the medical community has been aware of the co-occurrence of these two diseases for more than 100 years. Oppenheim has been credited as first describing the association, either in 1905 [14]. The incidence of TN in the general population, variably reported between studies, is into a range from 4.3 to 27 new cases per 100,000 people per year and a lifetime prevalence of 0.16-0.3% in population-based studies. Patients with MS have a 20-fold increased risk of developing TN [4]; TN is uncommon, but well-described phenomenon in patients with MS. Our series reports a prevalence of 8.8%, but studies reported a rate between 1.9% and 4.9% of patients with MS to suffer from this neuropathic pain condition [15,16], without differences between relapsing-remitting, secondary and primary progressive forms [15]; conversely MS is detected in 2%-14% of patients with TN [15], but it is still not well known in which number of cases the TN represents the onset symptom of MS. It just reported that TN in the majority appears after MS is up to 6% [17] but up to 10% report TN as the first sign of MS and it can predate a second MS episode by up to 10 years [12].

In our collection of 718 evaluated patients, TN was the presenting symptom of MS only in 0.4% of cases. Just another single-center study conducted in British Columbia [15], Canada, reported that only five of 1182 individuals evaluated from 1980 to 1992 had TN as the first presentation of MS, representing 0.4% of cases.

Foley et al. [18] reported that the overall prevalence of pain in MS is high, affecting more than 60% of individuals during their disease, without mentioning the onset of MS disease. Off the latter, a variable number is reported in the different studies of patients in which the pain is localized in the facial area [19-21]. [18] reported among 8590 SM patients’ respondents to a survey, that the prevalence of TN was 830 (9.7%). In the 588 participants with TN who reported the year that TN was diagnosed, TN preceded the diagnosis of MS in 88 (15%). In one study in which both current and lifetime TN were reported, the lifetime prevalence of TN was 4.0%, four-fold higher than the current prevalence (1.2%) [15,22]. Most studies that have compared the age at diagnosis of TN in individuals with and without MS have found that TN occurs at younger ages in those with MS [23,24].

In practice, despite the article’s title says that it is a common event, they report that about 1% of MS patients begin with TN [25]. The largest of these studies included participants from multiple centers but reported a low prevalence of TN of only 2%. This may reflect the focus on current pain symptoms at the time the study was conducted rather than on lifetime diagnoses of TN, as reported in the present study [26]. We suppose these clinical data are useful for the choice of treatment; Although associated with a pathologically distinct disease process, MS-associated TN may be indistinguishable from classical TN. In these patients, the clinical presentation of TN is grossly like for the primary form, although more prolonged background pain and atypical features are reported [9,24].

In MS patients with neuropathic facial pain, it may be unclear whether the pain is a sequela of MS plaques in the pons, which may affect trigeminal pathways but would not benefit from MVD, or of vascular compression in the [5,12,27] pontine cistern, which may benefit from surgical decompression. Collectively, the literature on treatment of TN in MS patients suggests that perhaps the pathophysiological mechanisms leading to their neuropathic facial pain cannot be simply dichotomized into patients with vascular compression and those with pontine plaques. [28-31]. A double insult mechanism for TN in MS patients was proposed by Truini et al. [32] after identifying co-occurrence of neurovascular compression and a demyelinating plaque to a greater degree ipsilateral vs. contralateral to facial pain in MS 31 patients with TN.

MS-related TN will often be very difficult to treat. Overall, up to 50% of patients with TN during first-line medical therapy (e.g., carbamazepine and oxcarbazepine) will experience a decline in the efficacy of these drugs in controlling their pain [33].

Rates of pain freedom in MS patients with TN have been reported in 20-74% of patients treated with [27,34,35] MVD, lower than for the general TN population. Given these concerns, some neurosurgeons will not offer MVD to patients with both TN and MS. However, withholding surgical treatment precludes offering potentially significant lasting relief to this vulnerable patient population [28]. In our study, we observed percentages like those previously reported in the literature of MS patients who have neuropathic facial pain as a manifestation of the disease’s onset. We didn’t find a significant difference in the age of onset of the two groups.

Nevertheless, our results and those available in the literature are quite homogeneous and lead us to affirm that the clinical onset of MS with TN represents a rather rare event, which occurs in 0.4-1% of cases. MS-related TN remains a challenge for neurologists and neurosurgeons owing to the lack of full comprehension of the complex pathogenesis at the basis of the onset of TN. PBC can be efficient in treating these patients [36].

CONCLUSION

Neuropathic pain is a common symptom in patients with MS. Is important to investigate the rate of debut of TN in SM patients to set up the correct diagnostic and therapeutic program. Among the different types of neuropathic pain, TN in MS patients are a difficult to treat with a relevant impact on the quality of life. Patients with MS experiencing TN find that daily life activities, work, mood, recreation and overall quality of life can be disrupted. TN constitutes a clinical picture frequently associated with the MS. Nevertheless, TN as a clinical manifestation of the onset of MS is a rare occurrence and is just noted that is rarely the first symptom of disease.

REFERENCES


